Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Reyataz

REYATAZ 50 mg oral powder · Abschnitt 4.5 · PDF-Seite 56–57

HOS-112197 · Präparat HOS-093615

56 Medicinal products by Interaction Recommendations therapeutic area concerning co-administration Fluticasone propionate The fluticasone propionate plasma levels Co-administration of intranasal 50 μg 4 times daily increased significantly, whereas the REYATAZ/ritonavir and these for 7 days intrinsic cortisol levels decreased by glucocorticoids metabolised by (ritonavir 100 mg capsules approximately 86% (90% confidence CYP3A4 is not recommended twice daily) interval 82%-89%). Greater effects may be unless the potential benefit of expected when fluticasone propionate is treatment outweighs the risk of And inhaled. Systemic corticosteroid effects systemic corticosteroid effects including Cushing’s syndrome and adrenal (see section 4.4). Inhaled/Nasal Corticosteroids suppression have been reported in patients A dose reduction of the receiving ritonavir and inhaled or glucocorticoid should be intranasally administered fluticasone considered with close propionate; this could also occur with other monitoring of local and corticosteroids metabolised via the P450 systemic effects or a switch to 3A pathway, e.g., budesonide. The effects a glucocorticoid, which is not a of high fluticasone systemic exposure on substrate for CYP3A4 (e.g., ritonavir plasma levels are yet unknown. beclomethasone). Moreover, in The mechanism of interaction is CYP3A4 case of withdrawal of inhibition. glucocorticoids, progressive dose reduction may have to be Concomitant use of REYATAZ (with or performed over a longer without ritonavir) and other Inhaled/Nasal period. Corticosteroids is expected to produce the same effects. Concomitant use of Inhaled/Nasal Corticosteroids and REYATAZ (with or without ritonavir) may increase plasma concentrations of Inhaled/Nasal corticosteroids. Use with caution. Consider alternatives to Inhaled/Nasal Corticosteroids, particularly for long-term use. ERECTILE DYSFUNCTION PDE5 Inhibitors Sildenafil, tadalafil, Sildenafil, tadalafil, and vardenafil are Patients should be warned vardenafil metabolised by CYP3A4. Co- about these possible side administration with REYATAZ may result effects when using PDE5 in increased concentrations of the PDE5 inhibitors for erectile inhibitor and an increase in PDE5- dysfunction with REYATAZ associated adverse events, including (see section 4.4). Also see PULMONARY hypotension, visual changes, and priapism. ARTERIAL The mechanism of this interaction is CYP3A4 inhibition. HYPERTENSION in this table for further information regarding co-administration of REYATAZ with sildenafil. GONADOTROPIN-RELEASING HORMONE (GnRH) RECEPTOR ANTAGONISTS Elagolix The mechanism of interaction is anticipated Concomitant use of elagolix increase in elagolix exposure in the 200 mg twice daily with presence of CYP3A4 inhibition by REYATAZ (with or without atazanavir and/or ritonavir. ritonavir) for more than 1 month is not recommended due to the potential risk of adverse events such as bone loss and hepatic transaminase elevations. Limit concomitant use of elagolix 150 mg once daily with REYATAZ (with or without ritonavir) to 6 months.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tadalafil (HOS-086316) fluticasone (HOS-108914) fluticasone propionate (HOS-086331) elagolix (HOS-112109) budesonide (HOS-086332) propionate (HOS-108915) sildenafil (HOS-086162) ritonavir (HOS-084521) beclomethasone (HOS-086334) vardenafil (HOS-086163)